{"id":"NCT02105272","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2014-04-07","resultsPosted":"2015-11-17","lastUpdate":"2015-12-21"},"enrollment":237,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"OPC-1085EL ophthalmic solution","otherNames":[]},{"type":"DRUG","name":"Latanoprost ophthalmic solution","otherNames":[]}],"arms":[{"label":"OPC-1085EL ophthalmic solution","type":"EXPERIMENTAL"},{"label":"Latanoprost ophthalmic solution","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy and safety of OPC-1085EL ophthalmic solution in comparison with latanoprost ophthalmic solution in subjects who are insufficiently responsive to latanoprost ophthalmic solution.","primaryOutcome":{"measure":"Decrease From Baseline in Intraocular Pressure","timeFrame":"Baseline, week 8 predose","effectByArm":[{"arm":"OPC-1085EL Ophthalmic Solution","deltaMin":2.9,"sd":null},{"arm":"Latanoprost Ophthalmic Solution","deltaMin":1.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":118},"commonTop":["Nasopharyngitis","Glucose urine present"]}}